Knockdown of cancerous inhibitor of protein phosphatase 2A may sensitize metastatic castration-resistant prostate cancer cells to cabazitaxel chemotherapy

详细信息    查看全文

• 作者：Jinming Huang (1)
  Jiaoyuan Jia (2)
  Qiang Tong (1)
  Jun Liu (1)
  Jun Qiu (1)
  Rong Sun (1)
  Lixin Yao (1)
  Chun Yang (3)
  
  1. Department of Urology ; 85 Hospital of PLA ; Shanghai ; China
  2. Department of Oncology and Hematology ; The Second Hospital ; Jilin University ; Changchun ; China
  3. Department of Urology ; Wuxi No.2 People鈥檚 Hospital affiliated to Nanjing Medical University ; Jiangsu ; China
  
• 关键词：Prostate cancer ; Cancerous inhibitor of protein phosphatase 2A ; Cabazitaxel ; Small interfering RNA ; Proliferation ; Chemoresistance
• 刊名：Tumor Biology
• 出版年：2015
• 出版时间：March 2015
• 年：2015
• 卷：36
• 期：3
• 页码：1589-1594
• 全文大小：1,016 KB
• 参考文献：1. Jemal, A, Siegel, R, Ward, E, Hao, Y, Xu, J, Thun, MJ (2009) Cancer statistics. CA Cancer J Clin 59: pp. 225-49 CrossRef
  2. Ren, SC, Chen, R, Sun, YH (2013) Prostate cancer research in China. Asian J Androl 15: pp. 350-3 CrossRef
  3. Huggins, C, Hodges, CV (2002) Studies on prostatic cancer: I. The effect of castration, of estrogen, and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. 1941. J Urol 168: pp. 9-12 CrossRef
  4. Suzman, DL, Antonarakis, ES (2014) Castration-resistant prostate cancer: latest evidence and therapeutic implications. Ther Adv Med Oncol 6: pp. 167-79 CrossRef
  5. Lassi, K, Dawson, NA (2010) Update on castrate-resistant prostate cancer. Curr Opin Oncol 22: pp. 263-7 CrossRef
  6. Tannock, I, Wit, R, Berry, W, Horti, J, Pluzanska, A, Chi, K (2004) Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 351: pp. 1502-12 CrossRef
  7. Singh, P, Yam, M, Russell, PJ, Khatri, A (2010) Molecular and traditional chemotherapy: a united front against prostate cancer. Cancer Lett 293: pp. 1-14 CrossRef
  8. Bono, JS, Oudard, S, Ozguroglu, M, Hansen, S, Machiels, JP, Kocak, I (2010) Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomized open-label trial. Lancet 376: pp. 1147-54 CrossRef
  9. Seruga, B, Ocana, A, Tannock, IF (2011) Drug resistance in metastatic castration-resistant prostate cancer. Nat Rev Clin Oncol 8: pp. 12-23 nonc.2010.136" target="_blank" title="It opens in new window">CrossRef
  10. Chen, M, Nowak, DG, Trotman, LC (2014) Molecular pathways: PI3K pathway phosphatases as biomarkers for cancer prognosis and therapy. Clin Cancer Res 20: pp. 3057-63 CrossRef
  11. Chen, KF, Liu, CY, Lin, YC, Yu, HC, Liu, TH, Hou, DR (2010) CIP2A mediates effects of bortezomib on phospho-Akt and apoptosis in hepatocellular carcinoma cells. Oncogene 29: pp. 6257-66 CrossRef
  12. Choi, YA, Park, JS, Park, MY, Oh, KS, Lee, MS, Lim, JS (2011) Increase in CIP2A expression is associated with doxorubicin resistance. FEBS Lett 585: pp. 755-60 CrossRef
  13. Thalmann, GN, Anezinis, PE, Chang, SM, Zhau, HE, Kim, EE, Hopwood, VL (1994) Androgen-independent cancer progression and bone metastasis in the LNCaP model of human prostate cancer. Cancer Res 54: pp. 2577-81
  14. Wu, D, Zhau, HE, Huang, WC, Iqbal, S, Habib, FK, Sartor, O (2007) cAMP-responsive element-binding protein regulates vascular endothelial growth factor expression: Implication in human prostate cancer bone metastasis. Oncogene 26: pp. 5070-7 CrossRef
  15. Pienta, KJ, Smith, DC (2005) Advances in prostate cancer chemotherapy: a new era begins. CA Cancer J Clin 55: pp. 300-18 CrossRef
  16. Qu, YY, Dai, B, Kong, YY, Ye, DW, Yao, XD (2013) Prognostic factors in Chinese patients with metastatic castration-resistant prostate cancer treated with docetaxel-based chemotherapy. Asian J Androl 15: pp. 110-5 CrossRef
  17. Petrylak, DP, Tangen, CM, Hussain, MH, Lara, PN (2004) Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 351: pp. 1513-20 CrossRef
  18. Seruga, B, Tannock, IF (2011) Chemotherapy-based treatment for castration-resistant prostate cancer. J Clin Oncol 29: pp. 3686-94 CrossRef
  19. Keizman, D, Maimon, N, Gottfried, M (2012) Metastatic hormone refractory prostate cancer: recent advances in standard treatment paradigm, and future directions. Am J Clin Oncol 37: pp. 289-96 CrossRef
  20. Kao, SC, Hovey, E, Marx, G (2011) Second-line therapy for castrate-resistant prostate cancer: a literature review. Asia Pac J Clin Oncol 7: pp. 212-23 CrossRef
  21. Lheureux, S, Joly, F (2012) Cabazitaxel after docetaxel: a new option in metastatic castration-resistant prostate cancer. Bull Cancer 99: pp. 875-80
  22. Wiegering, A, Pfann, C, Uthe, FW, Otto, C, Rycak, L, M盲der, U (2013) CIP2A influences survival in colon cancer and is critical for maintaining Myc expression. PLoS One 8: pp. e75292 CrossRef
  23. Zhang, S, Wang, Y, Chen, Z, Kim, S, Iqbal, S, Chi, A (2013) Genistein enhances the efficacy of cabazitaxel chemotherapy in metastatic castration-resistant prostate cancer cells. Prostate 73: pp. 1681-9
  
• 刊物主题：Cancer Research;
• 出版者：Springer Netherlands
• ISSN：1423-0380

文摘

Cancerous inhibitor of protein phosphatase 2A (CIP2A) is a recently identified human oncoprotein that can stabilize some proteins by inhibiting degradation mediated by protein phosphatase 2A (PP2A), and its level in cancer is associated with resistance to chemotherapy. However, whether CIP2A could increase chemoresistance of prostate cancer (PCa) cells to chemotherapeutic agent cabazitaxel remains unclear. To determine whether CIP2A serves as a potential therapeutic target of human PCa, we utilized small interference RNA (siRNA) to knock down CIP2A expression in human PCa cells and analyzed their phenotypic changes. The data demonstrated that CIP2A was significantly elevated in mCRPC cell lines C4-2 and ARCaPM at both the mRNA and protein levels. CIP2A silencing led to decreased proliferation and enhanced chemosensitivity and apoptosis to cabazitaxel in human PCa cells, as well as reduced Akt phosphorylation. Our data suggesting critical roles of CIP2A in PCa cells chemoresistance to cabazitaxel and raising the possibility of CIP2A inhibition as a promising approach for chemosensitization of metastatic castration-resistant prostate cancer (mCRPC).